Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Pomegranate Health

Maves
Graded #89

Higher grade

vs+2.3999999999999915
Pomegranate Health
Graded #122

Lower grade

The verdict

Maves takes it — 71.8/100 to 69.4/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +4
84
80
Dose & formulationMaves +1
65
64
Clinical oversightPomegranate Health +6
76
82
Labs & monitoringPomegranate Health +1
52
53
FulfillmentMaves +22
87
65
Contract termsEven
55
55
Maves · left barPomegranate Health · right bar

The numbers

MetricMavesPomegranate Health
WeighScore71.8/10069.4/100
GradeCC
Scorecard rank#89#122
Semaglutide$99/mo (starting dose, first-month rate, compounded)$119/mo (starting price, compounded)
TirzepatideNot disclosed$149/mo (Starter tier, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Pomegranate Health

Graded #122 · C

Strengths

  • No membership and no consultation fee — the site states 'No Membership required' and 'Transparent pricing, no hidden fees'
  • The semaglutide price sits in the product page's own static HTML, so it can be read before any intake
  • Shipping is included: 'shipped discreetly to your door at no extra cost'
  • Both semaglutide and tirzepatide are offered

Where it loses points

  • The tirzepatide price is not on the public site at all — it exists only inside the in-app pricing portal, and there is no standalone tirzepatide product page to read it from
  • Both published figures are floors, a 'Starts @' and a Starter tier, and no price is published for the dose you titrate up to
  • The states it can prescribe in are not disclosed anywhere; the dataset's own note records that semaglutide was unavailable in CA, IA and WI
  • Klarna, Afterpay and Affirm are offered at checkout, so any monthly figure seen in a financing widget is an instalment and not the medication price
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard